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Abstract
Precision medicine is an emerging approach for disease treatment 
and prevention that takes into account individual variability in genes, 
environment, and lifestyle for each person. Precision medicine is 
transforming clinical and biomedical research, as well as health care 
itself from a conceptual, as well as a methodological viewpoint, 
providing extraordinary opportunities to improve public health and lower 
the costs of the healthcare system. However, the implementation of 
precision medicine poses ethical-legal, regulatory, organizational and 
knowledge-related challenges. Without a national strategy, precision 
medicine, which will be implemented one way or another, could take 
place without the appropriate planning that can guarantee technical 
quality, equal access of all citizens to the best practices, violating the 
rights of patients and professionals and jeopardizing the solvency of the 
healthcare system. With this paper from the Spanish Societies of Medical 
Oncology (SEOM), Pathology (SEAP), and Hospital Pharmacy (SEFH) 
we highlight the need to institute a consensual national strategy for the 
development of precision medicine in our country, review the national 
and international context, comment on the opportunities and challenges 
for implementing precision medicine, and outline the objectives of a 
national strategy on precision medicine in cancer.
Resumen
La medicina de precisión es un enfoque emergente para el tratamiento y pre-
vención de las enfermedades que tiene en cuenta la variabilidad individual 
en los genes, el medio ambiente y el estilo de vida de cada persona. La me-
dicina de precisión está transformando la investigación clínica y biomédica 
así como la asistencia sanitaria, tanto desde un punto de vista conceptual 
como metodológico, ofertando oportunidades extraordinarias para mejorar 
la salud pública y reducir los costes del sistema sanitario. Sin embargo, la im-
plementación de la medicina de precisión supone un reto a nivel ético-legal, 
regulatorio, organizativo y de conocimiento. Sin una estrategia nacional, la 
medicina de precisión, que se implantará en cualquier caso, lo podría hacer 
sin la adecuada planificación que permita garantizar la calidad técnica, la 
equidad de los ciudadanos en el acceso a las mejores prácticas, vulnerando 
los derechos de pacientes y profesionales y arriesgando la solvencia del sis-
tema de salud. Con este artículo de las sociedades españolas de Oncología 
Médica (SEOM), Anatomía Patológica (SEAP) y Farmacia Hospitalaria (SEFH) 
señalamos la necesidad de establecer una estrategia nacional consensuada 
para el desarrollo de la medicina de precisión en nuestro país, revisamos el 
contexto nacional e internacional, comentamos las oportunidades y los retos 
para la implementación de la medicina de precisión, y delineamos los obje-
tivos de una estrategia nacional sobre medicina de precisión en el cáncer.
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Rationale
With this paper from the Spanish Societies of Medical Oncology 
(SEOM), Pathology (SEAP), and Hospital Pharmacy (SEFH), we propose 
to highlight the need to institute a consensual national strategy for the 
development of precision medicine in our country and promote its imple-
mentation in the clinical practice with equity and with assurances in terms 
of quality, efficiency, and legal guarantee, in addition to contributing to 
the sustainability of the healthcare system.
Introduction
There is no universal definition for the term “precision medicine”, 
although probably the most widely accepted is the one provided by the 
US National Institutes of Health (NIH) that defines it as “an emerging 
approach for disease treatment and prevention that takes into account 
individual variability in genes, environment, and lifestyle for each person”1. 
Though at times used interchangeably with personalized medicine, the 
National Research Council prefers the term precision medicine instead 
because personalized medicine might suggest that the different strategies 
for treatment and prevention are developed solely for each individual to 
the extent that “individual” refers to the specific individual and not in terms 
of belonging to a particular biotype, as is truly the case with precision 
medicine.
This definition gives rise to two fundamental consequences. On the one 
hand, it entails a change of paradigm in medicine, in that the approach 
to disease is founded on the genetic and molecular bases of health and 
disease in order to estimate risks and inform decisions regarding preven-
tion, diagnosis, and treatment. Illnesses previously considered as a single 
disease have now been disaggregated into several entities, with different 
causal mechanisms that call for different strategies. Inversely, diseases that 
were regarded as disparate must be approached from the same point of 
view, given that they have molecular mechanisms in common.
The concept of precision medicine necessarily involves modifying 
the point at which health care commences, understanding that patients’ 
treatment and needs depend more on their particular characteristics than 
the generic name of the disease. Likewise, knowing which nosological 
groups a person is predisposed to as an individual will make it possible to 
develop better prevention strategies. Furthermore, individuals take a more 
active role in their own health, by understanding their natural predisposi-
tion to suffer certain diseases.
Precision medicine has already become a reality in daily clinical prac-
tice in certain disciplines such as Oncology; not only is its implementation 
an ethical mandate and obligation of policy insofar as it represents an 
indisputable improvement in the treatment of patients and prevention of 
disease, but it has also been proven to foster the sustainability of the 
healthcare system in certain cases, by selecting patients with a greater 
likelihood of response, keeping patients from being exposed to expensi-
ve, unnecessary treatments, while minimizing complications derived from 
therapies with scant or no possibility of response, and enables the most 
efficient preventive actions to be selected for each individual.
International and national context and 
initiatives
By means of several national plans, the United States, United Kingdom, 
France, Germany, China, and other developed countries such as Finland 
and Estonia have implemented national strategies endowed with State 
funding to mobilize and strengthen the Industry and technological develo-
pment associated with precision medicine, channel the necessary private 
and public resources to put them into effect, improve infrastructure, and 
increase the current applications of this kind of medicine.
Internationally, the International Consortium for Personalised Medicine 
(ICPerMed), constitutes the most relevant project in Europe. It comprises 
the European Commission and more than 30 European and extra-Euro-
pean partners and funding agencies2. Its main objective is to stimulate 
research and the implementation of precision medicine by means of mee-
tings, workshops, conferences, surveys, strategic publications, and joint 
initiatives. It origin lies in the preparatory workshops organized by the Eu-
ropean Commission, together with several subsequent initiatives, including 
the seventh Framework Program and the establishment of EuroBioForum 
and the consortium of CASyM (www.casym.eu) in 20113.
In France, for example, the Institut National du Cancer (INCa) has 
an institutional framework to incorporate precision medicine into standard 
health care and the France Médecine Génomique Plan 2025, published 
in 2016 and with a projection until 2025, seeks to equip this country with 
the means and industrial structure it needs to introduce this new approach 
into health care and for this discipline to be placed as a driver of econo-
mic development in France4. Other countries, such as Estonia, Iceland, or 
the United Kingdom have developed initiatives to create population bio-
banks that make it possible to establish associations between biomarkers, 
clinical history, and lifestyle.
In the United States, the Precision Medicine Initiative, announced by 
then President Obama, allocated 216 million dollars in the 2016 fiscal 
year to fund a shared initiative of the NIH, the National Cancer Institute 
(NCI), the Food and Drug Administration (FDA), and the Office of the 
National Coordinator for Health Information Technology (ONC). The most 
distinctive aspect of this project is the creation of a database in which 
one million volunteers will provide genetic data, biological samples, and 
clinical information with the aim of predicting risk, understanding how and 
why common diseases occur and to improve diagnostic and treatment 
strategies5.
To date, a general strategy on precision medicine has not been deve-
loped at state level in Spain. Different National Strategies compile recom-
mendations for the development of precision medicine (for instance, the 
National Healthcare System’s Strategies in Cancer and Rare Diseases). 
Additionally, there are national initiatives, such as the one put forth by 
the National Institute of Health Carlos III (call for projects in the field of 
precision medicine, participation in the Network for Excellency for Re-
search and Innovation on Exosomes [REDIEX] or ELIXIR [a European inter-
governmental organization for lifescience resources], etc.); together with 
local projects, such as the Comprehensive Plan for Genomic Medicine in 
Catalonia, the Medical Genome Project in Andalusia, the Future Clinic 
project in the Valencian Region, or the MEDEA project in Extremadura6.
Opportunities
Precision medicine is a reality in practical clinical health care and has 
begun to shift the paradigms in medicine and even change how diseases 
are classified. In general, precision medicine enhances effectiveness and 
efficiency, since it makes it possible for the most appropriate strategies to be 
used for each patient on the basis of the molecular mechanism underlying 
the illness and the individual’s genetic variability. Furthermore, it fosters the 
application of the most suitable therapeutic scheme for patients, given that 
it factors in the genetic variability determining drug metabolism and phar-
macodynamics, together with the environmental factors that also play out 
in their disposition. Thus, it prevents exposing patients to drugs that are not 
useful for them, decreasing the possibilities of adverse events related to 
drugs with no possibility of response, as well as the secondary complica-
tions derived from treating patients with ineffective drugs and the loss of 
opportunity that this entails.
From an economic perspective, precision medicine is regarded as an 
opportunity to develop an industrial sector of high strategic, healthcare, 
scientific, and economic value. The incorporation of our country at an early 
stage would provide us with the chance to be technologically independent 
in a sector that is more and more necessary, and would also enable us to 
export knowledge and technology in a new industrial sector. All this repre-
sents an unprecedented economic opportunity in our country, that would 
call for a hefty investment and mobilization of all parties involved in order to 
achieve innovative technological solutions (that include the fields of industry 
and information technology) and a new form of economic development 
that enables the device to be sustained beyond its start-up and to respond 
to several technological challenges, in particular to the development of the 
necessary information technology capacities. Precision medicine is subject 
to international competition and our country should not remain on the side-
lines.
Finally, precision medicine is proposed as a tool to contribute to ratio-
nalizing healthcare expenditure and to the sustainability of the healthcare 
system; generating the data needed to generalize initiatives that demonstra-
te cost-effectiveness.
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Challenges
Ethical-legal and regulatory challenges
With the development of precision medicine, citizens and healthcare sys-
tems confront new challenges, such as that of maintaining the balance bet-
ween risks and benefits, bearing in mind the unprecedented ethical, econo-
mic, social, and legal implications, in particular with respect to data protection.
The identification of biomarkers and massive sequencing techniques are 
based on the collection and analysis of a tremendous amount of information 
(“big data”). In this context, it is imperative that the confidentiality of sensi-
tive personal data be guaranteed, especially in multicenter, multinational 
projects that call for the shared use of data, but also within the context 
of biobanks (despite the fact that donors are generally anonymous, some 
biobanks require that donors can be identified).
On the other hand, if samples are used for subsequent research, doubts 
may arise as to who actually holds the property rights over the samples, the 
validity of the consent that was given, or about the right to the information 
(or to non-information). This occurs to the degree to which genetic testing 
makes it possible to identify or confirm the mutations responsible for a disea-
se that will probably develop in the future or to identify a predisposition to 
developing it, when there are as yet no preventive techniques or effective 
treatments available for many of those genetic diseases. Clear regulations 
are therefore fundamental with the aim of guaranteeing that the principle of 
universal and equal access to healthcare be guaranteed. Furthermore, it is 
paramount that the risk of citizens being excluded on the basis of their ge-
netic data and their predisposition to suffer certain diseases be approached 
both legally and ethically.
The ethical dimension is an integral part of the implementation of an 
initiative of this nature. We must be able to respond to the ethical and legal 
issues that arise from the consent provided by citizens for the use of their 
health data and to the complications derived from data anonymization, the 
management of secondary discoveries and of untoward incidents.
Organizational and knowledge-related challenges
From a purely instrumental point of view, information technology systems 
must be put into place to enable the management and sharing of the vast 
amount of data generated by means of new generation sequencing tech-
niques (Big Data and Information and Communications Technologies [ITC] 
solutions). The transformation to precision medicine calls for new professio-
nal roles that are as yet not included in healthcare systems, thus requiring the 
involvement of professionals in the field of bioinformatics and other profes-
sionals that currently participate under the umbrella of research.
Moreover, clinical information and data from complementary testing are 
currently safeguarded by the healthcare profession and/or by the institution 
that performed the specific determinations; however, this model is not sui-
table for managing data coming from the next generation of sequencing 
and that could have future medical applications for individuals or for their 
descendants.
From a scientific perspective, precision medicine calls for an even grea-
ter understanding of the molecular bases of disease and of the interaction 
between genes and the environment.
Furthermore, studies must be initiated to evaluate the implementation of 
healthcare applications, which requires substantial investment and a multi-
disciplinary approach.
Likewise, genetic, pharmacogenetic, and “omic” sciences must be bols-
tered at the undergraduate and postgraduate levels of training; promoting 
the continuous education offer involving the leading scientific societies and 
establishing the accreditation of reference centers. Pharmacogenomics is 
one part of precision medicine, but it must be complemented with pharma-
cology in order for this new discipline to be created.
Even more important are the challenges associated with the paucity of 
knowledge the general population has regarding precision medicine. The 
acceptance of treatment or prevention recommendations can be difficult, 
especially bearing in mind that they deal with complex concepts and that 
the dissemination of mistaken ideas about a kind of genetic determinism 
without factoring in the modulating effect of lifestyle and environment, could 
lead to a feeling of defeatism and helplessness or, in contrast, could lead 
to society’s becoming “medicalized”, and instigate the performance of un-
necessary or dangerous testing, as well as to potentially mistaken decisions 
about reproduction.
In this regard, the creation of a national platform is decisive within the 
overall project for the incorporation of precision medicine that can analyze 
and control the translation of scientific findings to clinical practice.
Finally, we must be mindful of the fact that in this context, every new drug 
or technique can be developed for a relatively small proportion of patients, 
making it necessary for there to be other models to facilitate access to the 
market from a regulatory perspective.
Objectives of a National Strategy on Precision 
Medicine
Taking into account the benefits, as well as the challenges derived from 
this area of medicine, we set forth the following objectives of the different 
areas as being a priority:
Healthcare and quality objectives:
 – To raise awareness among the population and decision-makers about 
the importance of precision medicine in current medical and healthcare 
practice and its projections for the future.
 – To incorporate precision medicine into the Strategic Plans already in 
force and to prioritize it in national health and research strategies, giving 
it the importance that scientific evidence confers upon it in each case 
uniformly throughout the territory.
 – To facilitate access to precision medicine to all cancer patients, indi-
viduals with rare and common diseases that are susceptible to it by 
creating sequencing platforms that are capable of covering the whole 
country.
 – To guarantee that the techniques used are accurate and reliable, as-
suring the use of the best scientific evidence available in basic and 
translational research.
 – To facilitate the generation of information about health outcomes.
 – To develop the national legal framework to make the regulation from the 
European Parliament and the European Council regarding personal data 
protection and the free circulation data feasible as well as to develop 
those aspects left to national legislation.
Area of knowledge:
 – To accelerate the design and execution of genetics-based studies, ex-
ploring basic aspects of tumor biology and setting up a network of 
knowledge about oncology that generates data and enables it to be 
shared to stimulate information technology and scientific discoveries and 
to inform clinical decisions.
 – From a regulatory perspective, to promote the performance of academic 
studies on response prediction by means of biomarkers in those areas 
not covered by industry.
 – To foster the availability of comprehensive databases that are validated 
and accessible and that include genomic, biomedical, clinical, and li-
festyle information. To stimulate networking through corporate structures, 
enhancing the shared use and access to data regarding subpopulations, 
generated both within the framework of clinical trials, as well as in real 
life.
 – To organize technology that will make it possible to analyze starting up 
a national center that enables the genetic data generated to be proces-
sed and used and to offer services for current applications.
 – To develop training for healthcare professionals in the application of 
precision medicine in healthcare practice.
 – To promote studies that analyze how pharmacogenomics and pharma-
cokinetics relate to one another and how they relate to measures of 
health outcomes.
 – To stimulate university-level training in this new branch of knowledge and 
to develop the new competences and technology needed to respond to 
the challenge of using and interpreting data on a large scale.
 – To guarantee training of regulatory agents with the aim of maintaining 
the necessary regulatory structure that can guarantee innovation and 
make it possible to protect public health.
 – To promote citizens’ knowledge about health and disease by encoura-
ging the participation of volunteers.

























Farmacia Hospi ta lar ia 2017
l Vol. 41 l Nº 6 l 688 - 691 lProposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH
Efficiency and sustainability:
 – To put our country among the nations having the capacity to develop 
and apply precision medicine and, therefore, to export knowledge and 
technology.
 – To develop the necessary regulatory frameworks to guarantee a system 
to evaluate new drugs, biomarkers, and efficient diagnostic methods.
 – To foster a long-term economic model, capable of integrating and deve-
loping the industrial fabric needed to sustain the incorporation of preci-
sion medicine into health on a large scale.
 – To create an observatory that can monitor the evolution of this field of 
medicine in its medical, technological, ethical, and regulatory dimen-
sions.
 – To prepare the legal regulations and code of ethics that make it possible 
to respond to the ethical and legal demands associated with the collec-
tion, conservation, and treatment of clinical and genomic data.
Conclusion
Precision medicine is transforming clinical and biomedical research, as 
well as health care itself from a conceptual, as well as a methodological 
viewpoint, providing extraordinary opportunities to improve public health and 
lower the costs of the healthcare system. Without a national strategy, preci-
sion medicine, which will be implemented one way or another, could take 
place without the appropriate planning that can guarantee technical quality, 
equal access of all citizens to the best practices, violating the rights of patients 
and professionals and jeopardizing the solvency of the healthcare system.
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